Biotech | February 27, 2022
VBI’s 3-antigen Hepatitis B vaccine gets CHMP nod
If approved, PreHevbri will be the only approved 3-antigen hepatitis B vaccine for adults in the E.U.
If approved, PreHevbri will be the only approved 3-antigen hepatitis B vaccine for adults in the E.U.
N Yuvraj, Joint Secretary, Dept of Pharmaceuticals, Satish Reddy, Chairman, Dr Reddy’s Laboratories; Kiran Mazumdar Shaw, Executive Chairperson, Biocon Group; Sanjiv Navangul, MD & CEO, Bharat Serums and Vaccines and Shravil Patel, MD, Zydus Lifesciences discuss the way forward for the India pharma industry
The bulk drug plants that have already been commissioned include CDA, para amino phenol, atorvastatin, sulfadiazine, oxcarbazepine, levofloxacin, carbidopa and levodopa
The group had witnessed healthy revenue growth as revenue stood at Rs 251.14 crore in FY21.
he financing was significantly oversubscribed with high demand from both existing and new investors.
The RTP manufacturing facility will support the company's clinical studies and early commercial launch in North America and Europe
AIIA partners with Startup India with the aim to identify and support innovations and start-ups working in the Ayush sector
US $ 555,000 invested by Wavemaker Partners in pre-seed round
The investment in Indian clinical technology expertise in Hyderabad comes amid the clinical trials sector's move towards decentralised trials
The researchers are of the view that the new drug designing strategy demonstrated by them could also be adopted to treat retroviral infections.
Subscribe To Our Newsletter & Stay Updated
